News

Simcere Pharma has posted a net loss of RMB58.7m ($8.89m) for the fourth quarter of 2010, compared to a loss of RMB75.42m for the same period in 2009.

Additionally, Pyott will also continue to serve the company in his current roles as chairman of the board and CEO. Additionally, the new structure will allow Mr Pyott

Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Insys CEO Michael Babich said this is a tremendous achievement for

The company claims that SwabFlush is the only IV catheter flush syringe that provides a disinfection cap for needleless IV connectors, built into the plunger of the syringe.

Under the partnership, a fully cGMP-compliant analytical testing facility will be developed in Shanghai in 25,000-square-foot area by WuXi which will build, equip and operate the facility. Stability

OneWorld Health has received significant funding for this project from the Department for International Development (DfID) in the United Kingdom. Anacor Pharmaceuticals CEO David Perry said the company

The study did not show improvement in the symptoms of depression in patients treated with RG2417 when compared to placebo over the eight-week treatment period. Repligen said that

Multiple formulations were evaluated, some of which achieved mean cumulative drug permeation amounts much higher than the existing market leading product. On a comparative basis, the Alliqua patch

TOLMAR will use Pilgrim’s integrated solutions for corrective & preventive action (CAPA) and Document management. The company will also strengthen its compliance, improve operational efficiencies and achieve cost